TAmiRNA to highlight advances in EV characterization at GSEV meeting Hamburg

Vienna, Austria: –Biotech and diagnostic innovator TAmiRNA will be a prominent presence at the upcoming Autumn Meeting of the German Society for Extracellular Vesicles (GSEV).

TAmiRNA will contribute a poster to the GSEV scientific conference highlighting its recent work on the biodistribution of EVs. The poster will be presented by Magdalena Mecking.

EV characterization

TAmiRNA will also use the meeting’s networking sessions to highlight the unique EV characterization services to academic and industry researchers working on applications of EVs as biomarkers or therapies.

In particular, it can point to the advances it has made in transcriptomic analysis of both small (microRNAs) and larger (mRNA, long non-coding RNA) RNAs, using its NextGen sequencing miND® platform with its panel of spike-ins and multiomics capabilities.

About TAmiRNA

TAmiRNA specializes in technologies for profiling levels of blood-circulating miRNAs and developing multi-parametric classification algorithms (“signatures”). TAmiRNA uses these technologies to develop minimal-invasive diagnostic tests for drug development, early diagnosis, and prognosis of disease, and as companion diagnostic tests to support treatment decisions. Through its CRO business, TAmiRNA enables clients from academic to private sectors to perform high-quality RNA profiling of various sample types and offers a fully integrated service from RNA extraction to data analysis. TAmiRNA has optimized its workflows for the comprehensive analysis of EV small and long RNA cargo.

TAmiRNA is among Europe´s first companies that have CE-marked a microRNA-based test – hepatomiR® – which is intended for the diagnosis of liver function in liver cancer patients.

For TAmiRNA´s work on novel drug safety biomarkers, TAmiRNA receives funding from the Innovative Medicines Initiative 2 Joint Undertaking “TransBioLine” under grant agreement No. 821283. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. For its work on senescence-associated biomarkers, TAmiRNA is receiving funding from Eureka-Eurostars grant Ab-SENS. For its work on novel liver function biomarkers, TAmiRNA is receiving funding from the Vienna Business Agency as well as FFG.

More information available at: www.tamirna.com

About GSEV Autumn Meeting 2024

The German Society for Extracellular Vesicles (GSEV) is a network of more than 200 scientists and professionals working in the field of extracellular vesicles. The GSEV goal is to promote collaborative, high-quality, and high-impact research on extracellular vesicles and to support young researchers in their careers.

The society partners with international and European vesicle societies and programs to increase scientific exchange and progress in the EV field.

The 2024 GSEV Autumn Meeting is a two-day event opening October 1 at the Saalhaus in the North German city of Hamburg. The conference aims to place itself at the heart of innovation and discovery with a full scientific program featuring more than 25 expert speakers exploring different aspects of extracellular vesicle research.

The event is organized by GSEV with further information at https://www.gsev.org/

Resources

Click on TAmiRNA EV characterization services for further information.
Click on miND® pipeline for small RNA-sequencing to learn more about NextGen multiomic characterization.